SARAH KELLER: Open Payments
NPI 1548732894 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,916 in 110 payments from 12 companies in 2025. Trend: 2023 $1,950 · 2024 $2,037 · 2025 $1,916
Food & beverage: $1,916
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 56 | $760 |
| Janssen Biotech, Inc. | 21 | $531 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $222 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $124 |
| Lilly USA, LLC | 4 | $61 |
| Aimmune Therapeutics, Inc. | 3 | $56 |
| Madrigal Pharmaceuticals | 2 | $47 |
| Ardelyx, Inc. | 3 | $46 |
| Novo Nordisk Inc | 1 | $23 |
| Gilead Sciences, Inc. | 1 | $20 |
Products named: RINVOQ, TREMFYA, ENTYVIO, XIFAXAN, SKYRIZI, CREON, ZENPEP, REZDIFFRA.
Industry payments across KY — which companies pay providers there.
